Hydroxyurea potentiates the caspase-independent killing of B-cell lines by rituximab and GA101

Oncology Research

Volumn 20, Issue 12, 2013, Pages 545-555

  Daniels, Ian ^a   Abulayha, Abdulmunem ^b   Haynes, Andrew P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Biotechnology Research Centre   (United States)

Author keywords

Apoptosis; CD20; GA101; Hydroxyurea; Lymphoma; Rituximab

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; HYDROXYUREA; NOCODAZOLE; OBINUTUZUMAB; PROCASPASE 3; RITUXIMAB; STAUROSPORINE;

ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL KILLING; CELL POPULATION; CELL SYNCHRONIZATION; CONCENTRATION RESPONSE; DNA FRAGMENTATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CASPASES; CELL DEATH; CELL LINE; DRUG SYNERGISM; HUMANS; HYDROXYUREA;

EID: 84887097534     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13728687793353     Document Type: Article

References (39)

1. Van Meerten, T.; Hagenbeek A. CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin's lymphoma. Neth. J. Med. 67: 251-259; 2009.
2. Sehn, L. H. A decade of R-CHOP. Blood 116: 2000-2001; 2010.
3. McLaughlin, P.; Grillo-Lopez, A. J.; Link, B. K.; Levy, R.; Czuczman, M. S.; Williams, M. E.; Heyman, M. R.; Bence- Bruckler, I.; White, C. A.; Cabanillas, F.; Jain, V.; Ho, A. D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833; 1998. (Pubitemid 28363048)
4. Davis, T. A.; Grillo-Lopez, A. J.; White, C. A.; McLaughlin, P.; Czuczman, M. S.; Link, B. K.; Maloney, D. G.; Weaver, R. L.; Rosenberg, J.; Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of retreatment. J. Clin. Oncol. 18: 3135-3143; 2000.
5. Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22:7359-7368; 2003.
6. Rose, A. L.; Smith, B. E.; Maloney, D. G. Glucocorticoids and rituximab in vitro: Synergistic direct antiproliferative and apoptotic effects. Blood 100: 1765-1773; 2002. (Pubitemid 34925155)
7. Alas, S.; Ng, C. P.; Bonavida, B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin. Cancer Res. 8: 836-845; 2002. (Pubitemid 34742116)
8. Wanner, K.; Hipp, S.; Oelsner, M.; Ringshausen, I.; Bogner, C.; Peschel, C.; Decker, T. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B-cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br. J. Haematol. 134: 75-84; 2006.
9. Barboza, N. M.; Medina, D. J.; Budak-Alpdogan, T.; Aracil, M.; Jimeno, J. M.; Bertino, J. R.; Banerjee, D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol. Ther. 13: 114-122; 2012.
10. Vega, M. I.; Huerta-Yepez, S.; Jazirehi, A. R.; Garban, H.; Bonavida, B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24: 8114-8127; 2005. (Pubitemid 41759811)
11. Jazirehi, A. R.; Huerta-Yepez, S.; Cheng, G.; Bonavida, B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 65: 264-276; 2005. (Pubitemid 40070818)
12. Jazirehi, A. R.; Vega, M. I.; Chatterjee, D.; Goodglick, L.; Bonavida, B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL downregulation, and chemosensitization of non-Hodgkin's lymphoma B-cells by Rituximab. Cancer Res. 64: 7117-7126; 2004. (Pubitemid 39331025)
13. Vega, M. I.; Jazirehi, A. R.; Huerta-Yepez, S.; Bonavida, B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: Role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J. Immunol. 175: 2174-2183; 2005. (Pubitemid 41113823)
14. Beers, S. A.; Chan, C. H.; French, R. R.; Cragg, M. S.; Glennie, M. J. CD20 as a target for therapeutic type 1 and 2 monoclonal antibodies. Semin. Hematol. 47: 107-114; 2010.
15. Mossner, E.; Brunker, P.; Moser, S.; Puntener, U.; Schmidt, C.; Herter, S.; Grau, R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; Ferrara, C.; Sondermann, P.; Jager, C.; Strein, P.; Fertig, G.; Friess, T.; Schull, C.; Bauer, S.; Dal Porto, J.; Del Nagro, C.; Dabbagh, K.; Dyer, M. J.; Poppema, S.; Klein, C.; Umana, P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type 2 anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393-4402; 2003.
16. Dalle, S.; Reslan, L.; Besseyre de Horts, T.; Herveau, S.; Herting, F.; Plesa, A.; Friess, T.; Umana, P.; Klein, C.; Dumontet, C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol. Cancer Ther. 10: 178-185; 2011.
17. Madaan, K.; Kaushik, D.; Verma, T. Hydroxyurea: A key player in cancer chemotherapy. Expert Rev. Anticancer Ther. 12: 19-29; 2012.
18. Hong, S. H.; Hong, B. I.; Kim, D. C.; Rho, M. S.; Park, J. I.; Rha, S. H.; Jun, H. S.; Jeong, J. S. Involvement of mitogenactivated protein kinases and p21Waf1 in hydroxyurea- induced G1 arrest and senescence of McA-RH7777 rat hepatoma cell line. Exp. Mol. Med. 36: 493-498; 2004.
19. Jiang, R.; Zhang, J. L.; Satoh, Y.; Sairenji, T. Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji. J. Med. Virol. 73: 589-595; 2004. (Pubitemid 38857210)
20. Johnson, C. A.; Forster, T. H.; Winterford, C. M.; Allan, D. J. Hydroxyurea induces apoptosis and regular DNA fragmentation in a Burkitt's lymphoma cell line. Biochim. Biophys. Acta 1136: 1-4; 1992.
21. Vaughan, W. P.; Kris, E.; Vose, J.; Bierman, P. J.; Gwilt. P.; Armitage, J. O. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediategrade and high-grade malignant lymphoma. J. Clin. Oncol. 13: 1089-1095; 1995.
22. Schilsky, R. L.; Williams, S. F.; Ultmann, J. E.; Watson, S. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 5: 419-425; 1987. (Pubitemid 17045465)
23. Lee, J. Y.; Leonhardt, L. G.; Obeid, L. M. Cell-cycle-dependent changes in ceramide levels preceding retinoblastoma protein dephosphorylation in G2/M. Biochem. J. 334(Pt. 2): 457-461; 1998. (Pubitemid 28448590)
24. Zhang, M.; Raveche, E. S. Apoptosis induction in fludarabine resistant malignant B-1 cells by G2/M cell cycle arrest. Oncol. Rep. 5: 23-30; 1998.
25. Daniels, I.; Abulayha, A. M.; Thomson, B. J.; Haynes, A. P. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 11: 1013-1023; 2006. (Pubitemid 43876831)
26. Alduaij, W.; Ivanov, A.; Honeychurch, J.; Cheadle, E. J.; Potluri, S.; Lim, S. H.; Shimada, K.; Chan, C. H.; Tutt, A.; Beers, S. A.; Glennie, M. J.; Cragg, M. S.; Illidge, T. M. Novel type 2 anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies. Blood 117: 4519-4529; 2011.
27. Rezvani, A. R.; Maloney, D. G. Rituximab resistance. Best Pract. Res. Clin. Haematol. 24: 203-216; 2011.
28. Chow, K. U.; Sommerlad, W. D.; Boehrer, S.; Schneider. B.; Seipelt, G.; Rummel, M. J.; Hoelzer, D.; Mitrou, P. S.; Weidmann, E. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87: 33-43; 2002. (Pubitemid 34101111)
29. Lin, C. K.; Nguyen, T. T.; Morgan, T. L.; Mei, R. L.; Kaptein, J. S.; Kalunta, C. I.; Yen, C. F.; Park, E.; Zou, H. Y.; Lad, P. M. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM. Exp. Cell. Res. 244: 1-13; 1998. (Pubitemid 28480848)
30. Huyghe, P.; Dassonneville, L.; Fenaux, P.; Bailly, C. Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. Oncol. Res. 14: 235-245. 2004.
31. Zhang, G. S.; Liu, D. S.; Dai, C. W.; Li, R. J. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am. J. Hematol. 81: 242-255; 2006.
32. Ratain, M. J.; Schilsky, R. L.; Wojack, B. R.; Simon, T.; Senekjian, E. K.; Vogelzang, N. J. Hydroxyurea and etoposide: In vitro synergy and phase I clinical trial. J. Natl. Cancer Inst. 80: 1412-1416; 1988.
33. Schilsky, R. L.; Ratain, M. J.; Vokes, E. E.; Vogelzang, N. J.; Anderson, J.; Peterson, B. A. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin. Oncol. 19: 84-89; 1992.
34. Saito, B.; Shiozawa, E.; Yamochi-Onizuka, T.; Adachi, D.; Nakamaki. T.; Tomoyasu, S.; Omine, M.; Mitsuya, T.; Takimoto, M.; Ota, H. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathol. Int. 54: 667-674; 2004. (Pubitemid 39297291)
35. Caers, J.; Menu, E.; De Raeve, H.; Lepage, D.; Van Valckenborgh, E.; Van Camp, B.; Alvarez, E.; Vanderkerken, K. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br. J. Cancer 98: 1966-1974; 2008. (Pubitemid 351821559)
36. Gregory, C. D.; Rowe, M.; Rickinson, A. B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71 (Pt. 7): 1481-1495; 1990. (Pubitemid 20225848)
37. Yee, J.; White, R. E.; Anderton, E.; Allday, M. J. Latent Epstein-Barr virus can inhibit apoptosis in B-cells by blocking the induction of NOXA expression. PLoS One 6:e28506; 2011.
38. Krauer, K. G.; Burgess, A.; Buck, M.; Flanagan, J.; Sculley, T. B.; Gabrielli, B. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23: 1342-1353; 2004. (Pubitemid 38406830)
39. Jiang, R.; Kanamori, M.; Satoh, Y.; Fukuda, M.; Ikuta, K.; Murakami, M.; Sairenji, T Contrasting effects of hydroxyurea on cell growth and reduction in Epstein-Barr virus genomes in EBV-infected epithelioid cell lines vs. Burkitt's lymphoma cell lines. J. Med. Virol. 70: 244-252; 2003. (Pubitemid 36520633)